Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD. Read the Press Release

Biophytis Completes Recruitment of SARA-INT Phase 2b Study, Evaluating the Efficacy of Sarconeos (BIO101) in the Treatment of Sarcopenia. Read the Press Release

Biophytis Reports 2019 Full Year Results and Provides Operational Update. Read the Press Release

Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France. Read the Press Release

Biophytis Trading will resume on February 14th, 2020 at 09:00 CET. Read the Press Release

Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure. Read the Press Release

Biophytis shares trading is suspended pending a new press release. Read the Press Release

Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS. Read the Press Release

Interview of Stanislas Veillet, CEO of Biophytis by Didier Testot on the web Tv www.labourseetlavie.com (in French)

Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in sarcopenia, has now achieved over 50% patient recruitment. Read the Press Release

Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release

Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management Team. Read the Press Release